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INTRODUCTION
Human African trypanosomiasis (HAT), or sleeping sick-
ness, is a disease caused by infection with the protozoan
Trypanosoma brucei gambiense or Trypanosoma brucei rhod-
esiense, two morphologically identical subspecies of Trypano-
soma brucei. The two forms of the disease are transmitted by
tsetse ﬂies of the genus Glossina (order Diptera) and are re-
stricted to sub-Saharan Africa. Both are fatal if left untreated.
HAT is the prototype of a neglected disease, affecting the
poorest people of the poorest continent (120). The develop-
ment of new diagnostic tests and drugs has been severely af-
fected by this neglect. Fortunately, new sources of funding and
initiatives, such as the Drugs for Neglected Initiative (http:
//www.dndi.org), give some hope for the future (119).
The high toxicity of melarsoprol, the most widely used treat-
ment for second-stage (or neurological) HAT (97, 136), means
that both diagnosis and staging of the disease must be highly
accurate. The availability of accurate, practical, and cheap
screening and conﬁrmatory tests is vital for T. b. gambiense
HAT control programs, which are usually based on the elimi-
nation of the parasite’s human reservoir by mass screening of
the population and treatment of all infected persons. A correct
diagnosis of HAT is thus beneﬁcial for both infected individ-
uals and the community.
This review focuses on the ﬁeld diagnosis of T. b. gambiense
* Corresponding author. Mailing address: Travel and Migration
Medicine Unit, Geneva University Hospital, 24 rue Micheli-du-Crest,
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 HAT, which represents the highest burden of the disease. The
diagnosis of T. b. gambiense HAT outside Africa has recently
been reviewed elsewhere (56).
LIFE CYCLE AND BIOLOGY
T. brucei belongs to the genus Trypanosoma within the family
of Trypanosomatidae, a large group of unicellular protozoan
parasitic organisms, and the order of Kinetoplastida.I ti sa
spindle-shaped cell (20 to 30 by 1.5 to 3.5 m) with a single
ﬂagellum. This ﬂagellum emerges from the posterior end, runs
along the cell membrane, to which it is attached by an undu-
lating membrane, and extends beyond the anterior part of the
cell. The base of the ﬂagellum is associated with the kineto-
plast, a large particle containing the DNA of the single mito-
chondrion. The trypomastigote is the only form to be observed
in the mammalian host, whereas the epimastigote form occurs
during the development phase in the tsetse ﬂy. During the
entire life cycle, T. brucei cells multiply by binary ﬁssion and
are considered to be exclusively extracellular.
The life cycle of T. brucei is shown in Fig. 1. Infection of the
mammalian host starts with the bite of an infected tsetse ﬂy
(Glossina spp.), which injects the metacyclic trypomatigote
form of the parasite in its saliva before taking its blood meal.
The trypanosomes multiply locally at the site of the bite for a
few days before entering the lymphatic system and the blood
stream, through which they reach other tissues and organs
including the central nervous system (CNS). Two different
trypomastigote forms can be observed in the mammalian host:
a long, slender proliferative form and a short, stumpy nondi-
viding form. Both forms are taken up by the tsetse ﬂy, but only
the latter is able to complete the complex 2 to 3 week life cycle
in the ﬂy.
In the mammalian host, the trypomastigote cell is com-
pletely covered by a dense monolayer of identical glycoproteins
that protect the parasite against direct lysis by complement
(17). Only when speciﬁc antibodies are present against the
surface epitopes is the parasite destroyed. Thanks to a fasci-
nating mechanism of continuous antigenic variation, which has
been studied extensively in animal models, a small but sufﬁ-
cient fraction of the parasite population is able to evade the
mammalian host humoral immune response and proliferate
until the new surface antigen coat is recognized by a new
generation of speciﬁc antibodies, mainly of the immunoglob-
FIG. 1. Diagrammatic representation of the life cycle of T. b. gambiense and T. b. rhodesiense in humans and the tsetse ﬂy. Copyright Alexander
J. da Silva and Melanie Moser, Centers for Disease Control Public Health Image Library. Reprinted with permission from the Division of Parasitic
Diseases, Centers for Disease Control and Prevention, Atlanta, Ga.
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 ulin M (IgM) type. Up to 1,000 different genes encoding the
variant surface glycoproteins are present in the T. brucei ge-
nome (16, 126). This phenomenon explains the ﬂuctuating
number of circulating trypanosomes in the patient’s blood
(105), which contributes to the limited sensitivity of parasite
detection methods in clinical practice.
EPIDEMIOLOGY
It is estimated that 60 million people are exposed to HAT in
nearly 200 separate active foci from 36 sub-Saharan countries
but only 4 million to 5 million are under surveillance (136). The
location of endemic foci of HAT follows the patchy distribu-
tion of tsetse ﬂies found in a belt that stretches south of the
Sahara and north of the Kalahari desert (9), as shown in Fig. 2.
Despite the absence of reliable epidemiological ﬁgures, the
World Health Organization (WHO) reports that 300,000 to
500,000 people might be infected by the T. b. gambiense form
of the disease in Western and Central Africa (http://www
.who.int/mediacentre/factsheets/fs259/en/). The most severely
affected countries are the Democratic Republic of Congo, the
Republic of Congo, Angola, Central African Republic, and
Southern Sudan, where HAT has remerged during the last
decades mainly due to long-standing geopolitical instability
and subsequent erosion or collapse of control programs (81,
117, 129). T. b. gambiense is transmitted by the bite of tsetse
ﬂies of the Glossina palpalis or G. fuscipes groups. Human-
vector contact occurs mostly in forested rivers and shores but
is also peridomestic when huts are built in or near plantations
(18).
T. b. rhodesiense HAT is a zoonosis present in Eastern and
Southern Africa. Wild animals, including game animals, are
usually affected, but epidemics occasionally occur in domestic
animals and humans. The parasite is transmitted by the bite of
tsetse ﬂies of the Glossina morsitans or G. fuscipes groups, and
human-vector contact typically occurs in savanna woodland but
can be peridomestic during epidemics (18). The incidence of T.
b. rhodesiense HAT is currently much lower than that of T. b.
gambiense HAT, but large epidemics were observed in the past.
No more than 50 cases of HAT are diagnosed yearly outside
Africa (56). Visitors to some game parks in eastern Africa are
at particular risk for T. b. rhodesiense HAT (47, 115). Migrants
FIG. 2. Geographic distribution of major endemic foci of T. b. gambiense and T. b. rhodesiense human African trypanosomiasis in Africa (1995).
Reprinted from reference 136 with the permission of WHO/CPE.
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 from countries where T. b. gambiense is highly endemic can
have HAT that remains unrecognized for years (108).
Studies conducted in Western and Central Africa have failed
to ﬁnd an increased risk of HAT among human immunodeﬁ-
ciency virus (HIV) infected individuals, but no deﬁnite conclu-
sion can be drawn from the available data (68, 77, 96). More-
over, there have been no studies describing the clinical
presentation and the validity of diagnostic tests in coinfected
patients.
CLINICAL FEATURES
The clinical presentations of T. b. gambiense and T. b. rhod-
esiense HAT are remarkably different. While T. b. gambiense
HAT is generally a chronic illness that lasts for years, T. b.
rhodesiense HAT usually presents as an acute febrile illness
that is fatal within weeks or months if left untreated. Excep-
tions to this rule occur, since fulminant illness has been de-
scribed with T. b. gambiense infections and chronic disease is
caused by T. b. rhodesiense in the southern end of its distribu-
tion (15, 18, 21). The clinical features can be indicative of HAT
but are neither sufﬁciently sensitive (T. b. gambiense) nor spe-
ciﬁc (both species) to be used to detect all infected individuals,
conﬁrm the diagnosis, or stage the disease (12, 14, 26, 29, 46,
61). Diseases such as malaria, enteric fever, tuberculous men-
ingitis and HIV infection can mimic or even coexist with HAT.
Therefore, clinical suspicion must be conﬁrmed by laboratory
tests.
At the site of the infecting bite, parasites proliferate and,
after 5 to 15 days, occasionally lead to a nodule or ulcer called
a chancre (or trypanome) that spontaneously resolves within a
few weeks. In African patients, chancres are generally absent at
the time of diagnosis in both forms of HAT (14, 20). This
contrasts with the high prevalence of chancres observed in
European patients, in particular those infected by T. b. rhod-
esiense (26, 47). In the largest published review of Europeans
diagnosed with HAT, chancres were more frequently observed
in patients returning from Eastern Africa (46%) than in pa-
tients returning from Western or Central Africa (23%) (26).
T. b. gambiense Disease
After a long but variable initial asymptomatic period, pa-
tients with T. b. gambiense HAT can present with intermittent
nonspeciﬁc symptoms such as fever, fatigue, headaches, ar-
thralgia, and pruritus. The skin rash, often observed in patients
of European origin (26), is usually not visible on dark skin.
Transient limbs or face edema can occur. Enlarged, painless,
rubbery cervical lymph nodes in the posterior cervical triangle
were recognized as an alert sign for HAT long ago by Sir
Thomas Masterman Winterbottom, who noted that slave trad-
ers in the late 18th century used neck swelling as an indicator
of the sleepiness or abnormal behavior that made particular
slaves undesirable (9). However, enlarged cervical lymph
nodes may be atypical, absent (in up to 50% of patients), or
due to other causes (97). Splenomegaly is another nonspeciﬁc
sign and is more commonly found than hepatomegaly (14).
This highly variable clinical picture grossly corresponds to the
ﬁrst, or hemolymphatic, stage of the disease.
Later in the disease, neuropsychiatric symptoms and signs,
due to the CNS invasion by trypanosomes and the resulting
immune response (39), gradually become more prominent.
The interval between the start of the infection and the second,
or neurological, stage is in the order of months or years (18).
The neuropathogenesis of second stage HAT has been recently
reviewed (50). The clinical features can be grouped into cate-
gories such as psychiatric, motor, sensory, and sleep abnormal-
ities. The mental disturbance may include irritability, lassitude,
headache, personality change, and overt psychiatric presenta-
tions such as psychosis. Pyramidal (e.g., focal paralysis), extra-
pyramidal (e.g., rigidity and tremor), and cerebellar (e.g., dys-
arthria and ataxia) disorders are common. Delayed and
increased sensation to pain (Kerandel’s sign) can also be
noted. Reversal of the normal sleep-wake cycle, with daytime
somnolence alternating with nocturnal insomnia, is typical.
Weight loss and endocrine abnormalities such as amenorrhea
and impotence are also frequent complaints. If left untreated,
patients ultimately die from the consequences of severe wast-
ing, dysfunction of the immune system, deep coma, and sei-
zures, often due to bacterial infections such as pneumonia or
meningitis.
T. b. rhodesiense Disease
HAT due to T. b. rhodesiense infection presents as an acute
(sometimes fulminant) febrile illness starting 1 to 3 weeks after
the infective bite; it cannot be distinguished clinically from
other tropical fevers such as malaria, enteric fever, and bacte-
rial meningitis. Compared to T. b. gambiense illness, febrile
episodes are more pronounced and frequent and lymphade-
nopathy is usually generalized. Keratitis and conjunctivitis
have been observed. There is less demarcation between ﬁrst-
and second-stage illness, and CNS involvement can be clini-
cally limited to drowsiness and tremor (18, 39). Pancarditis
with congestive heart failure, arrhythmia, and pericardial effu-
sion can kill the patient before pronounced CNS involvement
becomes apparent (118). Most deaths (80%) occur within 6
months of onset of illness (88).
LABORATORY DIAGNOSIS OF T. B. GAMBIENSE
INFECTION
The diagnosis of T. b. gambiense HAT follows a three-step
pathway: screening, diagnostic conﬁrmation, and staging. The
majority of control programs rely on active case detection
through mass population screening. Screening tools therefore
need to be sensitive, practical, quick, and cheap. For that
purpose, the Card Agglutination Test for Trypanosomiasis
(CATT/T. b. gambiense), currently used in most areas of en-
demic infection, is a more efﬁcient screening method than the
cervical lymph node (CLN) palpation and puncture (103). Di-
agnostic conﬁrmation then relies on the ﬁnding of trypano-
somes in the blood, lymph nodes, or cerebrospinal ﬂuid (CSF).
Unfortunately, it is estimated that 20 to 30% of patients are
missed by the standard parasitological techniques (103). Stag-
ing of the disease is a key step that allows classiﬁcation of the
patient into the ﬁrst (hemolymphatic) or second (meningoen-
cephalitic) stage of the disease. In the absence of reliable blood
tests able to detect CNS invasion by the parasite, HAT staging
relies on the CSF examination.
136 CHAPPUIS ET AL. CLIN.M ICROBIOL.R EV.
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 It must be stated that the efﬁciency associated with imple-
menting accurate diagnostic tools in HAT control programs
based on active case ﬁnding can be offset by other crucial
determinants such as a low attendance rate of the population
or an insufﬁcient proportion of patients completing treatment
with subsequent cure (103).
Biological Parameters
Biological blood parameters such as increased sedimenta-
tion rate and low hematocrit reﬂect the systemic chronic in-
ﬂammation present in HAT patients and are therefore non-
speciﬁc. Thrombocytopenia is generally mild or absent, and
features of disseminated intravascular coagulopathy are not
found (37). Liver transaminase levels, bilirubin, and renal func-
tion tests are usually within normal limits or slightly elevated
(12). Protein measurements usually show decreased albumin
and increased immunoglobulin concentrations, especially of
IgM (12). Low serum C3 levels and split C3 products can be
found, reﬂecting complement activation (38). These ﬁndings
are of little use in most ﬁeld settings, where only the erythro-
cyte sedimentation rate and the hematocrit can be measured.
Antibody Detection
Indirect evidence for trypanosome infection can be obtained
by demonstrating speciﬁc antibodies in the blood, plasma, or
serum of infected hosts. Trypanosomes have a complex anti-
genic structure and elicit the production of a large spectrum of
antibodies. T. b. gambiense speciﬁc IgG and IgM antibodies are
present in high concentrations and are directed mainly against
the immunodominant surface glycoprotein antigens of the par-
asite. The type of antigen(s) used greatly determines the sen-
sitivity and speciﬁcity of the test. Current serological tests
detect antibodies after 3 to 4 weeks of infection (126). Sero-
positivity must be interpreted with caution in previously
treated patients since antibodies can persist for up to 3 years
after cure (91).
CATT/T. b. gambiense. Although not registered by any reg-
ulatory agency, the introduction of the CATT/T. b. gambiense
(CATT) for mass population screening has been a major
breakthrough in the diagnosis of T. b. gambiense HAT, limiting
the number of parasitological examination to patients found
with a positive serology. Developed in the late 1970s, the
CATT is a fast and simple agglutination assay for detection of
T. b. gambiense-speciﬁc antibodies in the blood, plasma, or
serum of HAT patients (74). The antigen consists of lyophi-
lized bloodstream forms of T. b. gambiense variable antigen
type LiTat 1.3. Antigen production is a fastidious process
based on the extraction of trypanosomes from infected rat
blood. The trypanosomes are then ﬁxed, stained with Coomas-
sie blue, and freeze-dried. The reagent, which is produced
under full quality control, is currently made only at the Insti-
tute of Tropical Medicine in Antwerp, Belgium, and ﬁeld kits
containing the reagent, control sera, and a 12/220-V card ro-
tator are available. One drop of reagent is mixed with one drop
of blood and shaken for 5 min on the rotator, and the result is
visible to the naked eye (Fig. 3). Up to 10 patients can be tested
at the same time, and hundreds of individuals can be screened
daily. The reported sensitivity of the CATT on undiluted whole
blood (CATT-wb) varies from 87 to 98%, and the negative
predictive value is excellent during mass population screening
(86, 93, 103, 112, 125, 136). Nevertheless, false-negative CATT
results can occur (94), as suspected in patients infected with
strains of trypanosomes that lack or do not express the LiTat
1.3 gene (27, 31). This could explain the lower sensitivity of the
CATT in some areas of endemic infection such as the Ethiope
focus in Nigeria, where an alternative serological test should be
used (30). Furthermore, when the CATT is performed on
undiluted blood or serum with low dilution (1:4), the agglu-
tination can be inhibited, a phenomenon called prozone. To
FIG. 3. Example of CATT performed on 10 serum samples diluted 1:4. Samples 1 to 3 are strongly positive, sample 4 is weakly positive, and
samples 5 to 10 are negative.
VOL. 18, 2005 FIELD DIAGNOSIS OF HUMAN AFRICAN TRYPANOSOMIASIS 137
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 overcome this problem, which is caused by complement factors
and affects the sensitivity of the test, addition of EDTA to the
dilution buffer has been proposed (89), substantially increasing
the sensitivity with only a minor loss in speciﬁcity (72, 111).
The CATT buffer supplemented with EDTA can remain stable
for at least 2 years at 45°C.
Despite a reported speciﬁcity of around 95%, the positive
predictive value of the CATT-wb remains limited because the
test is used for mass screening in populations where the prev-
alence of HAT is usually below 5% (86, 93, 103, 125, 127, 128,
138). False-positive results can occur in patients with malaria
and other parasitic diseases such as transient infection by non-
human trypanosomes (74). The speciﬁcity of the CATT is
further improved when performed on serum diluted to 1:4 (74,
126). This remains insufﬁcient for diagnostic conﬁrmation but
allows a signiﬁcant gain of time and ﬁnancial resources by
decreasing the number of parasitological investigations. The
validity of the CATT, when performed with higher serum di-
lutions, is discussed below.
The CATT can be performed with blood-impregnated ﬁlter
paper (FP) (85). This method is particularly useful for screen-
ing individuals who cannot be reached by full mobile teams
during active case ﬁnding. The micro-CATT, a protocol using
small quantities of both antigen (ca. one-ﬁfth of the standard
amount) and FP eluate (sample), showed promising results in
Co ˆte d’Ivoire (78, 85). The major constraint for widespread use
of the micro-CATT is the rapid decrease in sensitivity when FP
are stored for more than 1 day at ambient temperature (125).
Moreover, due to the minute volumes of antigen and test
sample used, reading and interpretation of the agglutination
patterns can be difﬁcult with the micro-CATT. A recently mod-
iﬁed method, the macro-CATT, was developed for testing
blood-impregnated FP by using a standard amount of antigen
and a higher volume of FP eluate. The macro-CATT was
evaluated in southern Sudan and showed a sensitivity of 91%
and excellent stability when FP were stored for up to 2 weeks
at ambient temperature (25 to 34°C) (23).
Other serological tests. The LATEX/T. b. gambiense has
been developed as a ﬁeld alternative to the CATT (19). The
test is based on the combination of three puriﬁed variable
surface antigens, LiTat 1.3, 1.5, and 1.6, coupled with sus-
pended latex particles. The test procedure is similar to the
CATT, including the use of a similar rotator. Compared to the
CATT, the LATEX/T. b. gambiense showed a higher speciﬁcity
(96 to 99%) but a lower or similar sensitivity (71 to 100%) in
recent ﬁeld studies conducted in several Western and Central
African countries (45, 93, 125). Further evaluations are needed
before it can be recommended for routine ﬁeld use.
Immunoﬂuorescence assays have been used with success for
HAT control in Equatorial Guinea, Gabon, and the Republic
of Congo, where they were shown to be highly sensitive and
speciﬁc (87). The availability of standardized antigen at low
cost has greatly improved the reliability of the test (73). It can
be used with serum or FP eluates, but the test sensitivity has
been reported to be as low as 75% when used with impreg-
nated FP (111). Enzyme-linked immunosorbent assay (ELISA)
methods can be performed with serum, FP eluates, and CSF
with strict standardization and quantiﬁcation (57). Interest-
ingly, ELISA could also detect speciﬁc antibodies in the saliva
from a group of 23 patients with conﬁrmed HAT (59). Anti-
body levels were about 250-fold lower than in the serum and
could not be detected by the CATT or the LATEX/T.b.gam-
biense in the vast majority of these patients. The sophisticated
equipment required for IFA and ELISA methods limits their
use to reference laboratories for remote testing of samples
collected in the ﬁeld during surveys.
Trypanosome Detection
Parasitological diagnosis is made by microscopic examina-
tion of lymph node aspirate, blood, or CSF. It provides direct
evidence for trypanosome infection and thus allows a deﬁnite
diagnosis. Unfortunately, parasite numbers in T. b. gambiense
infection can vary between more than 10,000 trypanosomes/ml,
being easily detectable, and less than 100 trypanosomes/ml,
being below the detection limit of the most sensitive methods
in use. Moreover, parasite detection can be rather labor-inten-
sive. Failure to demonstrate parasites therefore does not nec-
essarily exclude infection. Serial examination of blood on con-
secutive days can increase the test sensitivity but is rarely
performed in practice. When possible, it is recommended to
use methods that test a larger quantity of blood and/or that
facilitate trypanosome visualization to improve the sensitivity
of parasite detection. It is also essential to keep the time
between sampling and examination as short as possible to
avoid immobilization and subsequent lysis of trypanosomes in
the sample. Trypanosomes are rapidly killed by direct sunlight
but can survive for a few hours when the sample is kept in a
cool and dark place. We review here the main parasite detec-
tion methods that are currently available for ﬁeld use. A de-
tailed description of most of these tests, including ﬁgures, can
be found in the WHO Trypanosomiasis Control Manual (137).
Chancre aspirate. Trypanosomes can be detected in the
chancre a few days earlier than in the blood. The chancre is
punctured, and the ﬂuid obtained is microscopically examined
as a fresh or ﬁxed and Giemsa-stained preparation. This
method is very seldom applied in the ﬁeld because most infections
are detected much later, when the chancre has already
disappeared.
Lymph node aspirate. CLN palpation should be done sys-
tematically in all patients with a positive CATT result. When
enlarged CLN are present, they are punctured, the fresh aspi-
rate is expelled onto a slide, and a coverslip is applied to spread
the sample and facilitate the reading. The wet preparation is
then quickly examined by microscope (magniﬁcation, 400)
for the presence of motile trypanosomes. The technique is
simple and cheap. The sensitivity varies between 40 and 80%
depending on the parasite strain, the stage of the disease (sen-
sitivity is higher during the ﬁrst stage), and the prevalence of
other diseases causing lymphadenopathy (112, 127).
The yield of CLN palpation and puncture in patients with a
negative CATT is very low; between 1999 and 2001, trypano-
somes were observed in only 316 (0.18%) of 174,295 lymph
node aspirates from CATT-negative individuals in Democratic
Republic of Congo (112). The authors calculated that a mean
of 138 h of work per new case diagnosed would be necessary.
Furthermore, all positive lymph node aspirates found in 1,000
individuals from two endemic foci located in Angola and Cen-
tral African Republic were associated with positive CATT (112).
Systematic CLN palpation and puncture is therefore not cost-
138 CHAPPUIS ET AL. CLIN.M ICROBIOL.R EV.
 
b
y
 
o
n
 
J
u
l
y
 
2
3
,
 
2
0
0
8
 
c
m
r
.
a
s
m
.
o
r
g
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 effective for use with CATT-negative individuals (L. Lutumba
et al., submitted for publication) unless indicative clinical signs
are present.
Wet and thick blood ﬁlms. In wet blood ﬁlms, 5 to 10 lo f
ﬁnger prick blood is placed on a slide and examined microscop-
ically (magniﬁcation, 400) under a coverslip. Trypanosomes
can be seen moving between the erythrocytes (the movement
of the surrounding erythrocytes often attracts attention). De-
spite its very low sensitivity, with a detection limit as high as
10,000 trypanosomes/ml, corresponding to 1 parasite/200 mi-
croscope ﬁelds, this method is still used in some centers be-
cause of its low cost and simplicity. Giemsa- or Field’s-stained
thin blood ﬁlms have a similarly low sensitivity. Examination of
20 l of stained blood in a thick blood ﬁlm slightly improves
sensitivity, with a detection threshold of around 5,000 trypano-
somes/ml. It is the technique of choice for blood examination
only when no centrifuge is available (41), although it is quite
time-consuming (10 to 20 min per slide) and requires expertise
to recognize the parasite, which is frequently deformed in this
preparation. Apart from trypanosomes, other parasites such as
microﬁlaria and Plasmodium can be detected.
Microhematocrit centrifugation technique. The blood con-
centration technique of microhematocrit centrifugation
(mHCT), sometimes referred to as the capillary tube centrif-
ugation technique or as the Woo test, was developed more
than 30 years ago and is still in use in many HAT control
programs (133, 134). In brief, capillary tubes containing anti-
coagulant are ﬁlled three-quarters full with ﬁnger prick blood.
The dry end is sealed with plasticine. By high-speed centrifu-
gation in a hematocrit centrifuge for 6 to 8 min, trypanosomes
are concentrated at the level of the white blood cells, between
the plasma and the erythrocytes. The capillary tubes, mounted
in a special holder, can be directly examined at low magniﬁ-
cation (100 or 200) for mobile parasites. The sensitivity of
mHCT increases with the number of tubes examined, with an
estimated detection threshold of 500 trypanosomes/ml. The
optimal number of tubes has not been determined with cer-
tainty, but in most programs, six to eight tubes are prepared.
This technique is moderately time-consuming, and the con-
comitant presence of microﬁlaria in the blood can render the
visualization of the much smaller trypanosomes very difﬁcult.
Nevertheless, this relatively simple technique can be applied
during mass screening by mobile teams.
Quantitative buffy coat. The quantitative buffy coat (QBC;
Beckton-Dickinson), initially developed for the rapid assess-
ment of differential cell counts, has been extended to the di-
agnosis of hemoparasites including trypanosomes (7, 67). It has
the advantages of concentrating the parasites by centrifugation
and, by staining the nucleus and kinetoplast of trypanosomes
with acridine orange, allowing a better discrimination from
white blood cells. After high-speed centrifugation of the blood
in special capillary tubes containing EDTA, acridine orange,
and a small ﬂoating cylinder, motile trypanosomes can be iden-
tiﬁed by their ﬂuorescent kinetoplasts and nuclei in the ex-
panded buffy coat. UV light is generated by a cold light source
connected by a glass ﬁber to a special objective containing the
appropriate ﬁlter. This objective can be mounted on almost
every microscope. A darkroom is needed for the procedure.
The relative sophistication and fragility of the material pre-
vents its daily transport during active screening sessions.
The QBC is a very sensitive technique that is very appreci-
ated by most ﬁeld laboratory workers. It also allows the diag-
nosis of concomitant malaria, which is very useful for patient
care. With a 95% sensitivity for trypanosome concentrations of
450/ml, the QBC can detect more patients with low para-
sitemia than the mHCT when fewer than eight capillary tubes
are used (4). It is as sensitive as the mini-anion-exchange
centrifugation technique (mAECT) described below (4, 124).
Production of the QBC kit has been abandoned, but the man-
ufacturing of capillaries was recently resumed.
Mini-anion-exchange centrifugation technique. The
mAECT was introduced by Lumsden et al. (71), based on a
technique developed by Lanham and Godfrey (55). An initial
evaluation showed that the mAECT was more sensitive than
the thick blood ﬁlm and the mHCT (70). An updated version
has been described by Zillmann et al. (139). The technique
consists of separating the trypanosomes, which are less nega-
tively charged than blood cells, from venous blood by anion-
exchange chromatography and concentrating them at the bot-
tom of a sealed glass tube by low-speed centrifugation. The tip
of the glass tube is then examined in a special holder under the
microscope for the presence of trypanosomes. The large blood
volume (300 l) enables the detection of less than 100 trypano-
somes/ml, resulting in high sensitivity, but the manipulations
are quite tedious and time-consuming. mAECT columns are
now produced with the assistance of the Institute of Tropical
Medicine—Antwerp at Kinshasa, DRC. Studies validating this
newly produced version of mAECT are under way.
Stage Determination: Cerebrospinal Fluid Examination
In the absence of sufﬁciently speciﬁc clinical signs and blood
tests indicating the evolution from ﬁrst- to second-stage HAT,
staging of patients still relies on examination of CSF obtained
by lumbar puncture. It is a vital step in the diagnosis process.
Patients with ﬁrst-stage disease receive daily intramuscular
pentamidine for 7 to 10 days, a treatment associated with less
than 1% mortality, whereas patients with second-stage disease
are still treated in most centers with melarsoprol, an arsenical
derivative associated witha2t o1 0 %fatality rate (97). The
majority of deaths are due to treatment-related acute enceph-
alopathies (98, 136). Eﬂornithine (DFMO) is a safer treatment
than melarsoprol, but its complicated schedule (four intrave-
nous infusions per day for 14 days) and cost remain an obstacle
to a wide ﬁeld application.
According to WHO recommendations, second-stage HAT is
deﬁned by the presence in the CSF of one or more of the
following (136): (i) raised white blood cell count (5 cells/l),
(ii) trypanosomes, and (iii) increased protein content (370
mg/liter, as measured by the dye-binding protein assay). As
reviewed below, these criteria are not entirely satisfying and
might soon be modiﬁed by recent studies’ ﬁndings.
White blood cell count. The CSF white blood cell count is
the most widely used technique for stage determination. After
collecting the CSF sample, the cell count should be carried out
as soon as possible to prevent cell lysis. Due to the small
number of cells in normal CSF, cell-counting chambers should
have a volume of at least 1 l, such as the Fuchs-Rosenthal and
the Neubauer devices. It is not recommended to dilute the CSF
with Tu ¨rck solution since this solution can lyse trypanosomes.
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 If fewer than 20 cells/l are counted, it is recommended to
repeat the counting procedure and to calculate mean count
values. The CSF pleocytosis is of lymphocytic origin, consisting
mainly of B cells (40).
The 5-cells/l threshold for treatment decision is controver-
sial (12, 63, 80). Some countries use a threshold of 10 cells/l
(Equatorial Guinea) or even 20 cells/l (Angola and Co ˆte
d’Ivoire) in their national protocol (25, 63, 117). Patients with
6 to 20 cells/l in the CSF are sometimes referred to as being
in the “early second stage” or “intermediate stage” of the
illness. This group is in fact composed of individuals with or
without signs of neuroinﬂammation, as recently demonstrated
(63). This is further illustrated by the effectiveness of pentam-
idine in HAT patients with 6 to 20 cells/l of CSF in Co ˆte
d’Ivoire (25), while in a study in Uganda, patients with 11 to 20
cells/l or with evidence of intrathecal IgM synthesis (a reli-
able marker of neuroinﬂammation) had a lower cure rate,
suggesting that these patients should be treated with DFMO or
melarsoprol (62). In a smaller study in Angola, the relapse rate
after pentamidine treatment was similar in patients with 0 to 5
or 6 to 10 cells/l (106). These data support the increase of the
CSF cell threshold from 5 to 10 cells/l. Furthermore, one
should take into account the higher normal cell counts in
neonates (109).
There is a general agreement that patients with proven HAT
(trypanosomes seen in the lymph node or blood) and with 20
cells/l in CSF should be treated as having second-stage HAT.
In Me ´decins Sans Frontie `res and Malteser programs in Sudan
and Uganda, serologically suspected individuals (positive
CATT of 1:4) with negative parasitological examination and
20 cells/l in the CSF are treated as second-stage HAT
patients. This approach aims at partially compensating the
insufﬁcient sensitivity of trypanosome detection but exposes
some non-HAT patients to unnecessary treatment for second-
stage illness. It can be justiﬁed in areas with high HAT prev-
alence, especially where DFMO, a safer drug than melarso-
prol, is used as the ﬁrst-line treatment. Here again, the
availability of more sensitive parasite detection methods and
more precise staging tools would solve the controversy.
The morular cells of Mott, which are plasma cells with large
vacuoles containing IgM, are reported to be highly indicative
of HAT when found in the CSF (36, 39, 95). Mott cells are
rarely observed in the ﬁeld and can also be found in other
neuroinfectious diseases such as neurosyphilis (52).
Trypanosome detection. The ﬁnding of trypanosomes in
CSF allows immediate classiﬁcation of a patient as being in the
second stage of illness. It is important to examine the CSF
immediately after lumbar puncture, because trypanosomes in
CSF start to lyse within 10 min. Direct detection of trypano-
somes (e.g., during cell counting) is a simple and cheap tech-
nique but suffers from insufﬁcient sensitivity. Increased sensi-
tivity of trypanosome detection is obtained by centrifugation of
the CSF sample, especially when a double centrifugation
method is used (22). The latter method is relatively time-
consuming and requires two different types of centrifuges;
therefore, it is not applicable in every ﬁeld setting. A modiﬁed
and simpliﬁed single centrifugation of CSF using a sealed Pas-
teur pipette has been proposed as an alternative to double
centrifugation (79).
Some authors challenge the value of ﬁnding CSF trypano-
somes in patients with no sign of CSF inﬂammation (absence
of elevated protein and cell count of 20/l in the CSF) who
were shown to respond to pentamidine treatment (25, 62, 80).
Protein concentration. In normal healthy individuals, pro-
teins in the CSF consist mainly of albumin (70%) and IgG
(30%), both originating from the serum. Protein concentra-
tions in the CSF are elevated in HAT patients and range from
100 to 2,000 mg/liter (13, 63). Protein concentrations can also
be raised in ﬁrst-stage illness due to the diffusion in the CSF of
IgG, which can be present in very high concentrations in the
serum. Recent evidence suggests that the protein concentra-
tion threshold set by WHO (370 mg/liter) is too low and should
be raised to 750 mg/liter to reﬂect blood-brain barrier impair-
ment, astrocyte activation, and neurodegeneration (61, 63).
Despite its apparent simplicity, accurate determination of the
total protein concentration in CSF is rather difﬁcult. CSF pro-
tein concentrations obtained by different methods and differ-
ent standards are not comparable. As a consequence of the
sophistication of the methods, the absence of standardization,
the instability of reagents, and the limited (if any) added value
compared to CSF cell count (80), total protein measurement
for staging HAT is no longer recommended and has been
virtually abandoned in ﬁeld laboratories.
Antibody detection. It has been well known for several de-
cades that the CSF of second-stage HAT patients contains high
levels of immunoglobulins, especially IgM (12, 36, 54, 132). An
increased CSF IgM concentration has thus been considered by
some as a strong potential marker of second-stage HAT (39,
75).
The demonstration of intrathecal synthesis of immunoglobu-
lins strongly supports the diagnosis of neuroinﬂammatory dis-
eases. Immunoglobulins synthesized in the CNS need to be
discriminated from blood-derived immunoglobulins by calcu-
lation of the intrathecal fraction and antibody index (quanti-
tative approach) or by detection of oligoclonal antibodies
(qualitative approach) (101, 114). The origin and composition
of the CSF immunoglobulins have been recently studied in
experiments with large patients groups. As previously sus-
pected (36), these studies conﬁrmed that the elevated immu-
noglobulin concentration in the CSF is due to intrathecal syn-
thesis and that the dominant IgM presence was an early
marker of CNS invasion whereas blood-CSF barrier dysfunc-
tion was found late in the course of CNS involvement (13, 65).
These results were further conﬁrmed by studies of 272 HAT
patients from different areas of endemic infection, where in-
trathecal synthesis of IgM was found in 95% of patients with
second-stage illness (63). T. b. gambiense HAT can thus be
classiﬁed among neuroinﬂammatory diseases with a dominant
IgM immune response pattern in the CNS, like Lyme neu-
roborreliosis and, occasionally, neuro-syphilis (101).
Despite its relevance to stage determination, IgM detection
in CSF has not been carried out in the ﬁeld, owing to the lack
of simple and robust tests. A latex agglutination test for IgM in
CSF (LATEX/IgM) has recently been developed. It is de-
signed for ﬁeld use and remains stable at 45°C for more than
2 years. Following initial promising results (58), the LATEX/
IgM was evaluated with CSF samples from patients from sev-
eral countries where infection is endemic (60). CSF end titers
obtained by the LATEX/IgM paralleled the IgM concentra-
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 tions determined by nephelometry and ELISA. At a cutoff
value of 1:8, the sensitivity and speciﬁcity of LATEX/IgM for
intrathecal IgM synthesis were 89 and 93%, respectively. Fu-
ture prospective studies with large numbers of patients are
needed for LATEX/IgM validation.
Only a small proportion of the very large amount of IgM
produced during HAT is speciﬁc anti-trypanosome antibody
(39). Trypanosome-speciﬁc antibodies detected in the CSF by
indirect immunoﬂuorescence are speciﬁc for second-stage ill-
ness, whereas a comparison with serum values by calculation of
the antibody index is necessary when measurements are per-
formed by ELISA (54, 57, 69). However, these methods are too
sophisticated to be used in remote treatment centers. Unfor-
tunately, the ﬁeld-designed CATT/T. b. gambiense and LA-
TEX/T. b. gambiense lack sensitivity when used with CSF for
detection of anti-trypanosome immunoglobulins (19, 66, 69).
The CSF of HAT patients also contains antibodies with
other afﬁnities. Antibodies against brain-speciﬁc components
such as neuroﬁlaments and galactocerebrosides (GalC) have
been detected and may be promising markers of second-stage
illness (6, 61, 64). These autoantibodies, which might result
from the CNS damage and immune activation triggered by
trypanosome invasion, are associated with markers of neuroin-
ﬂammation such as the CSF cell count and protein and immu-
noglobulin concentrations (11, 61). Unfortunately, anti-GalC
antibodies detectable in the serum are not correlated with
neuroinﬂammation (11).
Management of Serologically Suspect Individuals
As previously stated, the parasitological methods have a
limited sensitivity and therefore do not allow all HAT patients
with an initial positive screening (usually a positive CATT on
whole blood and on a 1:4 serum dilution) to be conﬁrmed to
have the disease and receive treatment (136). These undiag-
nosed patients will return home and will either be diagnosed at
a later stage of the disease or simply die. Moreover, they
contribute to the reservoir of parasites and thus to transmis-
sion of the disease. One option is to examine these serologi-
cally suspect individuals at regular intervals (e.g., every 3
months) for 1 to 2 years (136). However, compliance with
follow-up visits is usually low, and the efﬁciency of this strategy
is poor (24).
A much more promising option is to determine a subgroup
of serologically suspected individuals at high risk of being in-
fected with T. b. gambiense and to treat them. Of 86 serolog-
ically suspect individuals (CATT serum, 1:4) being moni-
tored in Angola, 52% of individuals with a CATT plasma end
titer of 1:16 were diagnosed with HAT during follow-up but
none of the individuals with lower CATT end titers were di-
agnosed with disease (113). Similar results were obtained for a
group of 749 serologically suspect individuals (CATT, 1:4)
who were examined at least once during a 12-month follow-up
period in Kajo-Keji county, southern Sudan (24). Individuals
with a CATT plasma end-dilution titer of 1:16 had a 50%
person-year risk of being conﬁrmed with HAT during follow-
up, compared with a 10 and 14% person-year risk for 1:4 and
1:8 end-dilution titers, respectively. The authors of these stud-
ies recommend treatment for all serologically suspect individ-
uals with a CATT end titer of 1:16, when the prevalence of
HAT in the investigated population is sufﬁciently high. Which
prevalence threshold to choose remains an open question, but
it should probably be no less than 1%. In a study conducted in
a low-prevalence area in Co ˆte d’Ivoire, only one patient was
diagnosed with HAT during a 2-year longitudinal follow-up of
77 serologically suspect patients (33). However, the CATT
end-dilution titer was limited to 1:4 in this study. Other factors,
such as poor access to care and absence or limited availability
of parasitological diagnosis, should positively inﬂuence the de-
cision to perform titration of serum and treat individuals with
a CATT end titer of 1:16.
Example of a Field Diagnostic Algorithm for
T. b. gambiense HAT
There is no “one-size-ﬁts-all” algorithm for the diagnosis of
HAT. The positive predictive value of any diagnostic test varies
with the prevalence of HAT among the tested population.
Therefore, the diagnostic tree applied in a given area should be
adapted to decreasing disease prevalence. Nevertheless, there
is a need to decrease interprogram variations in the diagnostic
approach. A more standard diagnostic algorithm would im-
prove the external validity of the few studies conducted on the
diagnosis and treatment of this neglected disease. An example
of a diagnostic algorithm, adapted from a recent publication by
WHO experts (112), is shown in Fig. 4. This algorithm is
FIG. 4. Example of a ﬁeld algorithm for the diagnosis of T. b.
gambiense sleeping sickness according to data from Simarro et al.
(112).
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 particularly well suited for populations with a rather high dis-
ease prevalence (e.g., above 2%), such as individuals coming
on their own to the treatment center, who are more likely to
have symptoms and thus the disease, or individuals from a
highly active focus of infection. If the prevalence of the disease
is lower (e.g., below 1%), it will be more appropriate to set a
higher CATT dilution threshold before implementing the
time-consuming search for parasites in the blood (i.e., 1:8 in-
stead of 1:4). As stated above, the treatment of serological
suspect patients with a high CATT end-dilution titer (1:16)
would not be justiﬁed for populations with low disease preva-
lence. In this case, these individuals should return home and be
told to come for control visits if symptoms appear or worsen.
The choice of the method for detection of bloodstream
parasites will depend on the method’s performance (detection
threshold), the workload, the number and level of training of
laboratory workers, and the ﬁnancial resources. Blood concen-
tration methods such as the mHCT or the QBC should be
preferred to a wet or thick blood smear. The mAECT can be
performed sequentially after a negative mHCT, but the efﬁ-
ciency of this controversial strategy is still being studied.
As discussed above, the CSF cell count threshold deﬁning
the stage of the disease is still subject to debate. Considering
the growing evidence showing a good efﬁcacy of pentamidine
in HAT patients with 10 cells/l (25, 106), a threshold of 10
cells is proposed in this algorithm. A 5-cells/l threshold re-
mains justiﬁed though, particularly in programs using the less
toxic eﬂornithine as ﬁrst-line therapy for second-stage illness.
Current diagnostic algorithms for HAT tend to neglect in-
vestigations for other diseases such as malaria, typhoid fever,
tuberculosis, syphilis, and HIV-associated diseases. These con-
ditions can mimic or complicate T. b. gambiense HAT. The
inﬂuence of the varying prevalence of these diseases on the
validity of some key steps of the HAT diagnostic algorithm,
such as the thresholds for CATT end-dilution titer and the
CSF cell count, deserves further investigations.
Other Diagnostic Approaches
Antigen detection tests. Antigen detection is an attractive
concept that would allow, unlike methods detecting antibodies,
a distinction between active and cured HAT. By detecting
antigens released by noncirculating trypanosomes sequestered
in the liver, spleen, lymph nodes, or CNS, antigen detection
has the potential to improve the sensitivity of current parasi-
tological methods. Following promising results of speciﬁc an-
tigen detection by ELISA (83), the card indirect agglutination
test for trypanosomiasis (TrypTect CIATT; Brentec Diagnos-
tics, Nairobi, Kenya) was developed for ﬁeld use. A prelimi-
nary evaluation of the TrypTectCIATT showed a high sensi-
tivity compared to other parasitological techniques (82), but
the results of subsequent studies raised strong doubts about its
speciﬁcity (5).
In vitro culture and animal inoculation. When inoculated
into a suitable medium, viable trypanosomes multiply but are
not detected for days or weeks. A ready-for-use kit for in vitro
isolation (KIVI) has been developed (1). After inoculation of
5 to 10 ml of blood, the bottles are kept at ambient tempera-
ture. Bloodstream-form trypanosomes transform into prolifer-
ating large procyclic forms that can be detected within 3 to 4
weeks. The recorded sensitivity of the KIVI is variable (76, 121,
122). The yield of isolation of T. b. gambiense in rodents is low
unless neonatal, immunosuppressed, or particular (e.g., Mas-
tomys natalensis) rodents are used (136). The high cost and the
long delay before obtaining the result are deﬁnite obstacles to
routine ﬁeld use of these techniques.
PCR. Different assays now exist; however, none of them
have been validated for diagnostic purposes. PCRs targeting
repetitive sequences are in theory more sensitive than those
targeting low-copy or single-copy sequences like the recently
developed tests for distinguishing T. b. gambiense and T. b.
rhodesiense (43, 48, 99, 100, 110, 131).
In principle, PCR can be applied to any patient sample that
may contain trypanosome DNA, such as whole blood or buffy
coat, lymph node ﬂuid, or CSF. Samples should be stabilized in
special buffers or on FP. The FTA FP produced by Whatman is
particularly convenient since it is easy to handle and it protects the
DNA from degradation, unlike common FP. However, the
amount of sample that can be applied on ﬁlter paper is small, thus
limiting the chance to contain enough DNA for detection.
Samples should be protected from sunlight to avoid DNA degra-
dation. PCR results are not always unequivocal. Unexplained
false-negative and false-positive results were observed in CATT-
seropositive but parasitologically nonconﬁrmed persons and in
CATT-negative controls (33, 116). Also, the signiﬁcance of a
positive PCR on a CSF sample is unclear. True et al. report that
PCR is 100% sensitive compared to double centrifugation of
CSF, but Jamonneau et al. clearly demonstrate that a number of
patients with positive PCR results with CSF were successfully
treated with pentamidine, thus showing them to be in the ﬁrst
stage of the disease (44, 123). Efforts to simplify the PCR ampli-
ﬁcation method itself, such as using an isothermal ampliﬁcation
reaction and visualization of the PCR product by precipitation
(53) or by oligochromatography (P. Mertens et al., Abstr. 14th
Eur. Congr. Clin. Microbiol. Infect. Dis, abstr. P1842, 2004), may
facilitate PCR application in African countries, but PCR is deﬁ-
nitely not an option for ﬁeld diagnosis and for the time being is
restricted to research purposes.
Proteomic signature analysis. Proteomic signature analysis is
a promising technology that has been recently used with sera from
patients with HAT and other diseases (90). The accuracy of this
experimental method was high (100% sensitivity and 98.6% spec-
iﬁcity) but needs to be conﬁrmed in prospective studies. As the
authors stated, this method is impracticable in the ﬁeld but could
identify discriminating biomarkers that could lead to the devel-
opment of more conventional and simpler tests.
Imaging techniques. Neuroimaging techniques such as com-
puted tomography and magnetic resonance imaging are not
available in areas of endemic infection, except in few referral
centers. They reveal nonspeciﬁc features that are occasionally
useful to stage the disease. Brain magnetic resonance imaging
may show diffuse white matter abnormalities, ventricular en-
largement, hyperintensities in the basal ganglia, and signs of
meningitis (35, 107).
LABORATORY DIAGNOSIS OF T. B. RHODESIENSE
INFECTION
As stated above, T. b. rhodesiense HAT usually presents as
an acute febrile illness with rather nonspeciﬁc symptoms and
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 signs unless the initial characteristic chancre is present. Bio-
logical parameters are generally more abnormal than with T. b.
gambiense illness. Anemia may be severe, at least partly due to
decreased red cell survival (135). Thrombocytopenia may also
be severe and can be accompanied by other features of dis-
seminated intravascular coagulation (8, 34, 104).
There is still no equivalent to the CATT widely available for
the screening of T. b. rhodesiense HAT, despite promising
results from initial evaluations of simple agglutination tests
such as the trypanosomiasis agglutination card test, the procy-
clic agglutination test for trypanosomiasis, or a modiﬁed and
more practical version (3, 84, 92). Immunoﬂuorescence and
ELISA-based serological tests exist, but their reported sensi-
tivity is variable and they can be performed only in reference
centers with highly trained technicians (2, 49, 51). Field screen-
ing thus still relies on clinical symptoms and signs. The diag-
nostic conﬁrmation and staging of T. b. rhodesiense HAT are
based on the same methods as described above for T. b. gam-
biense disease. Parasitological conﬁrmation is relatively easy
because bloodstream trypanosomes are numerous (Fig. 5).
Most patients are therefore diagnosed by examination of a
stained thin or thick blood smear (26, 47). Trypanosomes are
sometimes detected by chance while searching for Plasmodium
spp (34, 115). Trypanosomes can also be found in the chancre
by microscopic examination of an aspirate, but other methods
such as lymph node aspiration or blood concentration tech-
niques are needed less often. Unlike T. b. gambiense HAT, the
staging of T. b. rhodesiense illness has not been recently studied
and thus still relies on WHO recommendations (136).
As stated above, T. b. rhodesiense infections have a more
chronic clinical presentation at the southern end of their dis-
tribution (e.g., in Zambia), with clinical characteristics closer
to those of T. b. gambiense illness (21, 102). A practical and
reliable serological test would be a useful screening tool in
these areas to detect infected individuals with few or no symp-
toms, since simple parasitological methods such as the thick
blood smear appears to have a more limited sensitivity in these
regions (20, 28).
There are currently no areas of endemicity where T. b.
gambiense and T. b. rhodesiense coexist. Endemic foci of both
forms exist in Uganda but are geographically separated. Evi-
dence of a northward spread of cattle carrying T. b. rhodesiense
has been recently shown (32, 42). A merger of T. b. gambiense and
T. b. rhodesiense foci would create huge problems, since the di-
agnosis and treatment of these two forms of illness differ consid-
erably (130). Molecular markers such as the serum resistance-
associated gene, present only in T. b. rhodesiense (131), and a
receptor-like ﬂagellar pocket glycoprotein (TgsGP) speciﬁc to T.
b. gambiense (10), may play a role in closely monitoring the dis-
tribution of both trypanosome species. The development of a
simple assay detecting the circulating serum resistance-associated
protein would not only be useful for targeting treatment to cattle
infected with T. b. rhodesiense (131) but would also be valuable to
distinguish the trypanosome species in humans exposed to both
forms of HAT.
CONCLUSION
Over the last few decades, only minor improvements have
been achieved in ﬁeld diagnosis of HAT. Parasite detection
remains insufﬁciently sensitive, and a simple serological diag-
nostic test for T. b. rhodesiense infection is still lacking. In
FIG. 5. Bloodstream trypomastigote forms of T. b. rhodesiense on a peripheral thin blood smear. Copyright Jean Jannin (WHO/CPE).
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 contrast, extensive research has been conducted on stage de-
termination and molecular diagnosis, which eventually may
lead to a new generation of ﬁeld-applicable tests. Since the
prevalence of HAT is expected to decrease as a result of
ongoing control activities, new diagnostic tests should be highly
speciﬁc. In the meantime, major diagnostic challenges for the
coming years are to improve the access of the existing tools for
the population at risk and their rational use in the diagnostic
strategy. All this will require determined dedication from sci-
entists from countries with endemic infection and Western
countries, WHO, nongovernmental organizations, policy mak-
ers, and donors.
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